PharmaDrug Inc CEO Daniel Cohen tells Proactive the group has formed a clinical trial agreement with the Johns Hopkins University to conduct a clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed, potently active comparator molecule.
Cohen says the Toronto-based company's clinical research collaboration builds upon its existing strategy of focusing on establishing a better understanding of the basic mechanisms by which DMT exerts its effects in the brain and elsewhere in the body.
It has an exclusive option to obtain a commercialization license to all rights, title, and interest that JHU may have or obtain in any invention that results from the clinical study.